| Autor: |
Nevala-Plagemann C; Division of Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Conroy T; Department of Medical Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France.; Inserm INSPIIRE, Université de Lorraine, Nancy, France., Garrido-Laguna I; Division of Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. Ignacio.Garrido-Laguna@hci.utah.edu. |
| Jazyk: |
angličtina |
| Zdroj: |
Nature reviews. Clinical oncology [Nat Rev Clin Oncol] 2024 Dec; Vol. 21 (12), pp. 902. |
| DOI: |
10.1038/s41571-024-00953-4 |
| Abstrakt: |
Competing Interests: Competing interests C.N.-P. receives institutional research funding from Theriva and has had an advisory role at Seagen. I.G.-L. receives institutional research funding from Revolution Medicine, Quanta Therapeutics, 280 Bio, Bayer, BridgeBio Pharma, Bristol–Myers Squibb, GlaxoSmithKline, Incyte, Jacobio, Lilly, MedImmune, Novartis, Pfizer, Repare Therapeutics, Sumitomo Dainippon Pharma Oncology and Tolero Pharmaceuticals; has had consulting or advisory roles at Jazz, Kanaph, Lilly, OncXerna Therapeutics and SOTIO; and an uncompensated consulting role for Revolution Medicine. T.C. declares no competing interests. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full text from SpringerLink